Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Tirzepatide 2.5mg weekly

"Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen)~Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses."

DRUG

Placebo injection (normal saline)

Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.

Trial Locations (1)

2010

Garvan Institute of Medical Research, Sydney

All Listed Sponsors
lead

Garvan Institute of Medical Research

OTHER

NCT06820281 - Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Biotech Hunter | Biotech Hunter